Current Cancer Drug Targets
Volume 21, 11 Issues, 2021
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research
Contents
Current Cancer Drug Targets, Volume 19 - Number 1
Biography Open Access
Preface Open Access
Commentary Open Access
Targeted Nanotechnology from Bench to Bedside
, 19(1): 3 - 4Konstantinos Sapalidis, Christoforos Kosmidis, Stela Laskou, Athanasios Katsaounis, Stylianos Mantalobas, Ioannis Passos, Nikolaos Michalopoulos, Aikaterini Amaniti, Chrysa Sardeli and Paul Zarogoulidis*
DOI: 10.2174/156800961901181204130142
Review Article
Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases
, 19(1): 5 - 16Oliesia Gonzalez Quiñones and Maria Bernadete Riemma Pierre*
DOI: 10.2174/1568009618666180430125201
Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases
Review Article
Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression
, 19(1): 17 - 25Liwei Lang, Austin Y. Shull and Yong Teng*
DOI: 10.2174/1568009618666180319091731
Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression
Review Article
Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?
, 19(1): 26 - 40A.P. Alves, A.C. Mamede, M.G. Alves, P.F. Oliveira, S.M. Rocha, M.F. Botelho and C.J. Maia*
DOI: 10.2174/1568009618666180430144441
Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?
Systemic Review Article
Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety
, 19(1): 41 - 49Mingxia Wang, Guanqi Wang, Haiyan Ma and Baoen Shan*
DOI: 10.2174/1568009617666170623115846
Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety
Research Article
The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy
, 19(1): 50 - 64Yiting Yin, Xin Qi, Yuan Qiao, Huaxiang Liu, Zihan Yan, Hao Li and Zhen Liu*
DOI: 10.2174/1568009618666181003170027
The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy
Research Article
Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate
, 19(1): 65 - 73Marzieh Ghanemi, Aminollah Pourshohod, Mohammad Ali Ghaffari, Alireza kheirollah, Mansour Amin, Majid Zeinali* and Mostafa Jamalan*
DOI: 10.2174/1568009617666170427105417
Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate
Research Article Open Access
Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
, 19(1): 74 - 80Peng Liu, Hailin Tang, Jiali Wu, Xingsheng Qiu, Yanan Kong, Lijuan Zhang, Xinhua Xie* and Xiangsheng Xiao*
DOI: 10.2174/1568009618666180709163718
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
COPE Compliant
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 5.2
Webmaster Contact: info@benthamscience.net